title: [Combined treatment for pain from bone metastases in patients with prostate cancer].
abstract: OBJECTIVE
  To evaluate the effects of combined treatment of hormone therapy with strontium-89 for pain from bone metastases in patients with prostate cancer.
  
  
  METHODS
  Sixteen patients with metastasis prostate cancer received hormone therapy with strontium-89 chloride (89Sr), and 4 of them received radiotherapy.
  
  
  RESULTS
  The pain was relieved. Relief occurred in 75.6% of the patients for 3 months, 80.5% for 6 months and 63.4% for 9 months.
  
  
  CONCLUSIONS
  Hormone therapy enhances the effect of 89Sr without obvious toxicity. The combined treatment not only significantly raises pain palliation, prolongs pain-free survival, but improves the patients life quality.
authors.affiliation: Department of Urology, Shanghai Ninth People's Hospital Affiliated to Shanghai Second Medical University, Shanghai 200011, China. renxmb@online.sb.cn
authors.forename: Xiaomin
authors.initials: X
authors.lastname: Ren
authors.forename: Jun
authors.initials: J
authors.lastname: Ying
authors.forename: Dehong
authors.initials: D
authors.lastname: Yao
authors.forename: Chuanyang
authors.initials: C
authors.lastname: Ye
authors.forename: Yueqing
authors.initials: Y
authors.lastname: Jiang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000503:physiopathology* / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010148:Intractable Pain / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000628:therapy*; D013324:Strontium / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; C025700:strontium chloride; D013324:Strontium